A drug used in the treatment of cystic fibrosis has been launched by a firm in Bognor.

Profile Therapeutics is one of the world's leading companies in the field of respiratory care.

It has three specialist divisions and Profile Pharma has just been granted UK marketing authorisation for Promixin.

The drug is for the treatment of chronic lung infection in cystic fibrosis patients.

It is the first inhaled drug to be developed by the company and is now available with Profile's new Prodose Adaptive Aerosol Delivery (AAD) system.

It is an "intelligent" inhaler that gives a measured dose of antibiotic faster than normal nebulisers.

The company is planning to to take the new drug into other EU countries and it anticipates the first licence will be granted in about 12 months.

Chief executive John Lisle said: "Gaining our first drug licence represents a significant step and should have a great impact on our development and prospects."

The company was focusing on its moving forward its pharmaceutical business but would retain and build on its business in other sectors.

He said: "The licence demonstrates we can bring low-cost and low-risk drugs to market, while the service package Promixin comes with, revitalises the drug.

"It's great for both patients and doctors because, among other things, it helps ensure the correct dosage."

When Promixin is prescribed by doctors, patients can receive the Prodose inhaler and a programme of patient support.

Mr Lisle said: "We're delighted to provide our first specialist pharmaceutical to the UK cystic fibrosis community and overseas launches will follow in due course."

The company has also entered into a European supply and licence agreement with Breath Limited to expand its pipeline of respiratory drugs.

Profile and Breath have also agreed a joint venture to develop and market a range of respiratory products in the North American homecare market from 2005 onwards.

Wednesday May 14 2003